Clinical studies consistently show that a significant portion of lost weight returns after discontinuing GLP-1 therapy, because these medications manage a chronic condition rather than cure it
Therefore, the behavioural and molecular effects observed in the present study should be interpreted as being consistent with either direct central actions or indirect peripheral-central signalling, rather than as definitive evidence that s.c
The 8mg Retatrutide dose produced 22.8% weight loss with lower side effect rates than 12mg
Summary Keywords glucagon-like peptide-1 receptor, Alzheimers disease, diabetes mellitus, insulin resistance, neuroinflammation Citation Li S, Huang N, Wang M, Huang W, Shi J, Luo Y and Huang J (2025) GLP-1R as a potential link between diabetes and Alzheimers disease